Gilead Sciences (GILD) Interest Expenses (2009 - 2026)
Gilead Sciences' (GILD) quarterly Interest Expenses came in at $240.0 million in Q1 2026, down 7.69% YoY from $260.0 million in Q1 2025, and down 5.88% on a QoQ basis from $255.0 million in Q4 2025.
Gilead Sciences (GILD) Interest Expenses (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Interest Expenses data on file, last reported at $240.0 million in Q1 2026.
- Quarterly Interest Expenses fell 7.69% year-over-year to $240.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 4.91% YoY) and the FY2025 annual result came in at $1.8 billion, up 27.93% from the prior year.
- Interest Expenses declined to $240.0 million in Q1 2026, from $255.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.4 billion in Q1 2023 to a low of $198.0 million in Q4 2022.
- A 5-year average of $885.4 million and a median of $255.0 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses jumped 34.5% — and 2024, when it slumped 90.03%.
- Tracing GILD's Interest Expenses over 5 years: stood at $198.0 million in 2022, then climbed by 0.51% to $199.0 million in 2023, then advanced by 12.06% to $223.0 million in 2024, then advanced by 14.35% to $255.0 million in 2025, then slipped by 5.88% to $240.0 million in 2026.
- The last three Interest Expenses figures came in at $240.0 million (Q1 2026), $255.0 million (Q4 2025), and $256.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247.00 Mn |
| Jun 30, 2026 | 247.00 Mn |
| Mar 31, 2026 | 240.00 Mn |
| Mar 31, 2026 | 240.00 Mn |
| Dec 31, 2025 | 255.00 Mn |
| Dec 31, 2025 | 255.00 Mn |
| Sep 30, 2025 | 256.00 Mn |
| Sep 30, 2025 | 256.00 Mn |
| Jun 30, 2025 | 254.00 Mn |
| Jun 30, 2025 | 254.00 Mn |
| Mar 31, 2025 | 260.00 Mn |
| Mar 31, 2025 | 260.00 Mn |
| Dec 31, 2024 | 223.00 Mn |
| Dec 31, 2024 | 223.00 Mn |
| Sep 30, 2024 | 238.00 Mn |
| Sep 30, 2024 | 238.00 Mn |
| Jun 30, 2024 | 237.00 Mn |
| Jun 30, 2024 | 237.00 Mn |
| Mar 31, 2024 | 254.00 Mn |
| Mar 31, 2024 | 254.00 Mn |